E fisiopatologia di kanser di pulmon ta referí na e kambionan den e prosesonan i mekanismo fisiológiko normal ku ta tuma lugá den desaroyo i progreso di kanser di pulmon.
Kanser di pulmon ta un malesa kompliká ku ta surgi di kresementu i divishon no kontrolá di sèlnan abnormal den pulmon.
E sèlnan aki por forma tumor i plama na otro parti di kurpa, loke ta kousa diferente síntoma i komplikashon.
E fisiopatologia di kanser di pulmon ta enbolbí diferente faktor, inkluyendo mutashonnan genétiko, faktornan ambiental i estilo di bida.
Mutashonnan genétiko por okurí den DNA di sèlnan di pulmon, kondusí na kresementu i divishon di sèlnan sin kontrol.
E mutashonnan aki por ta heredero òf adkiri, i nan por ta kousa di eksposishon na kanser, manera huma di tabaku, radon, asbesto i polushon di airu.
Kanser di pulmon por wordu klasifiká den dos tipo prinsipal: kanser di pulmon di sèl chikitu (SCLC) i kanser di pulmon di sèl no chikitu (NSCLC).
E fisiopatologia di e tipo di kanser di pulmon aki por ta diferente, pasobra nan tin diferente mutashon genétiko i ta respondé diferente na tratamentu.
E fisiopatologia di kanser di pulmon ta enbolbí tambe e interakshon entre e sèlnan di kanser i e tehido ku ta rondoná nan, inkluyendo e sistema inmunológiko.
Celnan canceroso por evadi e sistema inmunologico, permitiendo nan crece y plama sin control.
Ademas, e mikroambiente di e tumor por promové kresementu di e tumor i metástasis dor di proveé un ambiente di sosten pa e sèlnan di kanser.
E fisiopatologia di kanser di pulmon ta un proseso kompleho i dinámiko, i investigadónan ta traha kontinuamente pa komprondé mihó e mekanismo di tras pa desaroyá tratamentunan mas efektivo i mehorá resultado di pashènt.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
['Disclaimer: médiko']
['E website aki ta pa informashon i edukashon so i no ta pa duna konseho médiko òf servisio profeshonal.']
['E informashon ku ta ser duná no mester ser usá pa diagnostiká òf trata un problema di salú òf malesa, i esnan ku ta buska konseho médiko personal mester konsultá ku un dòkter ku tin un pèrmit di traha.']
['Por fabor nota e reda neuronal ku ta generá kontesta na e preguntanan, ta spesialmente inakusá ora ta trata di kontenido numériko. Por ehèmpel, e kantidat di hende diagnostiká ku un malesa spesífiko.']
['Semper busca conseho di bo dokter of otro profesional di salud cualifica tocante un condicion medico. Nunca ignora conseho medico profesional of tarda pa busca esaki pa motibo di algo cu bo a lesa riba e website aki. Si bo ta kere cu bo por tin un emergencia medico, yama 911 of bay na e sala di emergencia mas cerca di bo mesora.']
['Copyright: Copyright']
['E Digital Millennium Copyright Act di 1998, 17 U.S.C. § 512 (e DMCA) ta duna derechi di rekurso pa doñonan di derechi di outor ku ta kere ku material ku ta aparesé riba internet ta violá nan derechi bou di lei di derechi di outor di Merka. ']
['Si bo ta kere di buena fe ku kualke kontenido òf material ku ta disponibel riba nos website òf servisio ta violá bo derechi di outor, abo (òf bo representante) por manda nos un notifikashon pa pidi pa kita e kontenido òf material òf pa blokia akseso na dje.']
["Mester manda e anunsio por eskrito via e-mail (wak e sekshon 'Kontacto' pa e-mail adrès)."]
['E DMCA ta eksigí ku bo notifikashon di violashon di derechi di outor ta inkluí e siguiente informashon: (1) deskripshon di e obra ku ta suheto di violashon; (2) deskripshon di e kontenido ku ta viola i informashon sufisiente pa nos por lokalisá e kontenido; (3) informashon di kontakto, inkluyendo bo adrès, number di telefòn i email; (4) un deklarashon di bo ku bo ta kere ku e kontenido no ta outorisá pa e doño di derechi di outor, su agente òf lei.']
['(5) un deklarashon di bo, firma bou di pena di huramentu falsu, ku e informashon den e notifikashon ta korekto i ku bo tin outoridat pa hasi uso di e derechonan di outor ku ta ser akusá di a wòrdu infringi;']
['i (6) un firma físiko òf elektróniko di e doño di derechi di outor òf un persona outorisá pa aktua na nòmber di e doño di derechi di outor.']
['Si bo no duna tur informashon ariba menshoná, e tratamentu di bo keho por tarda.']
['Kontakto']
['Por fabor manda nos un email ku kualke pregunta/sugerencia.']
What is pathophysiology of lung cancer?
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Tokante']
['BioMedLib ta usa kòmpiuter outomátiko (algoritmo di siñamentu di mashin) pa generá par di pregunta i kontesta.']
['Nos ta kuminsá ku 35 mion publikashon biomédico di PubMed/Medline. Tambe página di RefinedWeb.']
